
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is anticipated to increase its FY26 revenue and EPS guidance due to strong first-quarter performance, favorable currency dynamics, and mitigated tariffs. The launch of the Affera product, which is expected to outperform competing systems, is projected to drive enhanced growth in the Cardiac Ablation segment. Additionally, the company's commitment to technological advancements aims to improve procedure outcomes, contributing to a positive outlook on its financial trajectory.
Bears say
The financial outlook for Medtronic appears negative due to anticipated revenue growth slowing to low-single digits, primarily attributed to unsuccessful new product launches and loss of market share in key categories, which could lead to below-consensus earnings. Additionally, the company faces significant risks, including competition from new product launches, disappointing sales performance, and potential adverse currency impacts that may further pressure margins. Furthermore, while acquisitions aimed at enhancing growth could prove beneficial in the long term, they may result in near-term dilution, complicating the company's earnings growth trajectory.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares